Project Grant R21HL184214
Award Date 5/25/26
Completion Date 4/30/27
Dollars Obligated $234K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tempe, AZ 85287, USA
Similar Awards
- Federal Grant Award Summary Colorado State University received a $1.31M Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The project develops and validates Electrical Impedance Tomography (EIT) as a noninvasive, real-time functional imaging technique to assess respiratory function in patients with muscular dystrophies. EIT addresses a...
- Federal Project Grant Award Summary Arizona State University received a $974,377 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) awarded September 4, 2025, with completion targeted for August 31, 2029. The award supports development of a wireless biomarker sensing system utilizing multi-band reconfigurable intelligent surfaces (RIS) to non-invasively monitor cardio-respiratory signals and assess sleep...
- Federal Grant Award Summary National Jewish Health received a $702,103 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion anticipated June 30, 2029. The project investigates the SFTA2/ADGRF5 signaling axis in alveolar homeostasis, focusing on elucidating how the secreted protein SFTA2 (surfactant-associated protein 2) regulates pulmonary surfactant levels through...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $676,459 to the University of Arizona on September 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of hexokinase 3 (HK3) in macrophage polarization and cardiac remodeling following myocardial infarction. The research project, extending through June 30, 2029, will generate scientific knowledge regarding how HK3 deletion enhances macrophage repair phenotypes...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Pittsburgh a $688,163 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and concluding May 31, 2029. This research grant supports an investigator-initiated project examining indole metabolites as xenobiotic danger signals in acute lung injury. The principal investigator, a physician in pulmonary and critical care medicine at the...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $744,880 to the University of Colorado-Denver through the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a four-year research project running from September 1, 2025, through May 31, 2029. The research investigates epimetabolic regulation of macrophage activation during acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), focusing on how lactate produced by...
- Federal Project Grant Award Summary The University of Arizona received a $1.57 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded June 5, 2026, with completion targeted for February 29, 2028. The grant supports basic science research investigating ATF6 (Activating Transcription Factor 6) as a regulator of endoplasmic reticulum (ER) proteostasis in atrial myocytes. The research focuses on...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Illinois a Project Grant of $1,603,296 on September 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mechanistic research into endotoxin-induced protection against allergic asthma. The research will be performed in Chicago, Illinois, with a completion date of May 31, 2029. The project deliverables include scientific investigation into how early...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the Regents of the University of Colorado–Denver a Project Grant totaling $111,626 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period August 1, 2025, through July 31, 2027. This research initiative focuses on investigating macrophage populations as a therapeutic target to attenuate pulmonary hypertension (PH) associated with sickle cell disease (SCD). The project will deliver...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Missouri System $461,115 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research assessing dissolved phase 129-Xenon (129Xe) as a biomarker for gas-exchange and vascular function in asthma patients. The project, extending through June 30, 2029, will utilize hyperpolarized 129Xe magnetic resonance imaging (MRI) technology to non-invasively...